Outpatient treatment options to address the SARS-CoV-2 variant Omicron
| Autor: | Matthew W, McCarthy |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Expert Review of Anti-infective Therapy. 20:1129-1133 |
| ISSN: | 1744-8336 1478-7210 |
| DOI: | 10.1080/14787210.2022.2077191 |
| Popis: | On 26 November 2021, the World Health Organization's Technical Advisory Group on SARS-CoV-2 Virus Evolution designated PANGO lineage B.1.1.529 a variant of concern and gave it the designation Omicron. The following day, the United Kingdom reported its first two cases of Omicron, a novel variant that was thought to be more transmissible than other variants such as Delta, Beta, and Alpha.Omicron has since become the dominant variant around the world, accounting for unprecedented case counts and hospitalizations. Omicron's high rate of spread has been attributed to a variety of factors, including enhanced replication in the upper airways (bronchi) as well as immune evasion.These intrinsic factors have implications for the approach to treatment. Monoclonal antibody therapies, which were highly effective against prior SARS-CoV-2 variants, were rendered largely ineffective against Omicron, and other antiviral options remain severely limited due to supply issues. This manuscript reviews the landscape of Omicron therapeutics and looks ahead to examine how these treatments and others may be used in the future to address the expanding threat of the Omicron variant. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|